Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T Sep 07 | 2022New Abecma KarMMa-9 Trial for Newly Diagnosed MM PatientsAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Sep 02 | 2022Precision Appoints Cindy Atwell as CBO and Jeff Smith as CRO; Derek Jantz to Act as CEO’s PartnerAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Sep 01 | 2022Gilead / Kite Expands Cell Therapy Operations in Brazil, Singapore, and Saudi ArabiaAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Aug 30 | 2022Thoughts on Kymriah’s ≥3L r/r FL Approval in Japan; Could Kymriah’s Price Decrease? Novartis’s APAC Market Expansion StrategyAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Aug 16 | 2022Gracell’s GC012F IND Submission Plans; Ph2 Portion of GC007 Trial to Start in Q3 2022; Gracell’s Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Aug 16 | 2022No Cell Therapy-Related Updates in August’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T Aug 12 | 2022P-PSMA-101 Clinical Program Delayed; Poseida’s Global Collaboration with Roche; Poseida Q2 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Aug 11 | 2022Abecma’s Ph3 KarMMa-3 Trial Meets Primary Endpoint; Potential Delays for bbT369 and SC-DARIC33; 2seventy bio Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Aug 10 | 2022BMS Reports Positive Topline Results From Abecma’s Ph3 KarMMa-3 Trial for ≥3L MM vs SoC: Will Abecma be the First Approved CAR-T in ≥3L MM?Access Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Aug 10 | 2022FDA to Potentially Clear ALLO-501A’s Pivotal Study in Q3 2022; Nirogacestat Combo Deprioritized; Data from ALLO-316 Delayed to 2023; Allogene Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, TCR Aug 09 | 2022Data Updates from Gavo-cel and TC-510 in H2 2022; TCR2 Tx Expands Its Manufacturing Capacity; TCR2 Tx Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Aug 08 | 2022Precision's Cash Runway Extended to YE 2024; No Major Clinical Updates; Precision BioSciences Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Aug 08 | 2022Thoughts on Poseida’s Strategic Global Collaboration with RocheAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD123, CD22 Aug 05 | 2022UCART20x22 Receives FDA IND Clearance; Novel Universal CAR-T Program; No Clinical Milestone Updates for UCART22, UCART123, or UCARTCS1; Cellectis’s Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Aug 04 | 2022Obe-cel’s Data Update Expected in Q4 2022; Afami-cel’s BLA Remains on Track for Q4 2022; Adaptimmune to Slow Down ADP-A2M4N7X19's Development; Autolus and Adaptimmune Q2 2022 Earnings SummariesAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Aug 03 | 2022Gilead Reports Outstanding Cell Therapy Revenue Growth; Yescarta's Manufacturing Capacity Scaled to Address Demand; Updated Regulatory Milestones for Yescarta and Tecartus in the EU; Gilead’s Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR Aug 02 | 2022You May Have Missed: Are Cell Therapy Leaders Losing Their Innovative Edge?Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Aug 01 | 2022Gracell Appoints Wendy Li as Chief Medical OfficerAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Jul 28 | 2022Abecma's Sales Increase While Breyanzi’s Revenue is Affected by Manufacturing Issues; No Clinical Milestone Updates for Breyanzi or Abecma; Oxford Biomedica's Expanded LSA Agreement; BMS’s Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, TCR Jul 27 | 2022Updated Guidance for Lete-cel; GSK / Haleon Business Separation Completed; GSK’s Q2 2022 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.